EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia

a b s t r a c t To test the recently developed EUTOS score in predicting optimal response to imatinib and the long-term outcome, 265 patients with early chronic phase chronic myeloid leukaemia treated with standard dose imatinib were analysed. Achievement of optimal response endpoints were higher in low-risk patients, though the difference was not statistically significant: PCyR at 6th month 86% vs 67% (p = 0.06), CCyR at 12th month 80% vs 63% (p = 0.09), MMR at 18th month 61% vs 36% (p = 0.11). However, EUTOS score was predictive for the long-term response. With a median follow-up of 61 months, 53% high-risk patients experienced imatinib failure, compared to 23% in the low-risk group (p = 0.013). Among high-risk patients, 4/17 (23%) progressed to accelerated/blastic phase or died, compared to 11/248 (5%) low-risk patients, with 5-year progression-free survival rates of 84 ± 10% and 96 ± 1%, respectively (p = 0.04). Our data confirm that EUTOS score envisions the long-term outcome of imatinib therapy. © 2013 Elsevier Ltd. All rights reserved.